Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART)
Authors:
Open Access
- 8 November 2021
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 19 (1) , 1-11
Abstract
Background: Sarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart failure. While corticosteroids have been used as a treatment for over 50 years, they are associated with hypertension, diabetes, and weight gain, further increasing cardiovascular risk. Interleukin-1 (IL-1) is the prototypical proinflammatory cytokine that works to activate the nuclear transcription factor NF-kB, one of the targets of glucocorticoids. IL-1 also plays an important role also in the pathophysiology of heart disease including atherosclerosis, myocardial infarction, and myocarditis.Methods: Building on a network of research collaborators developed in the Cardiac Sarcoidosis Consortium, we will investigate the feasibility and tolerability of treatment of CS with anakinra at two National Institute of Health Clinical and Translational Science Award (CTSA) hubs with expertise in cardiac sarcoidosis. In this pilot study, up to 28 patients with cardiac sarcoidosis will be recruited to compare the administration of an IL-1 blocker, anakinra, 100 mg daily on top of standard of care versus standard of care only for 28 days and followed for 180 days. Utilizing surrogate endpoints of changes in systemic inflammatory biomarkers and cardiac imaging, we aim to determine whether IL-1 blockade with anakinra can combat systemic and cardiac inflammation in patients with cardiac sarcoidosis.Discussion: The current trial demonstrates an innovative collaborative approach to clinical trial development in a rare, understudied disease that disproportionately affects females and minorities.Trial RegistrationThe trial was registered prospectively with ClinicalTrials.gov on July 12, 2019, identifier NCT04017936.Keywords
Funding Information
- National Center for Advancing Translational Sciences (TR003103-01, TR003103-01, TR003103-01)
- American Heart Association (19CSL0134580004, 19CSL0134580004, 19CSL0134580004, 19CSL0134580004)
- Pauley Heart Center (Pilot Grant, Pilot Grant)
This publication has 44 references indexed in Scilit:
- Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart FailurePLOS ONE, 2012
- Improved Detection of Myocardial Involvement in Acute Inflammatory Cardiomyopathies Using T2 MappingCirculation: Cardiovascular Imaging, 2012
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- Detection of Myocardial Damage in Patients With SarcoidosisCirculation, 2009
- Corticosteroid treatment in sarcoidosisEuropean Respiratory Journal, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac SarcoidosisJACC, 2005
- Corticosteroids for pulmonary sarcoidosisCochrane Database of Systematic Reviews, 2005
- Prostacyclin for pulmonary hypertension in adultsCochrane Database of Systematic Reviews, 2005
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003